Role of CYP2D6 in the N-hydroxylation of procainamide

被引:26
作者
Lessard, E
Fortin, A
Belanger, PM
Beaune, P
Hamelin, BA
Turgeon, J
机构
[1] LAVAL HOSP, QUEBEC HEART INST, Ste Foy, PQ G1V 4G5, CANADA
[2] UNIV LAVAL, FAC PHARM, Ste Foy, PQ G1V 4G5, CANADA
[3] CHU NECKER ENFANTS MALAD, INSERM, U75, F-75730 PARIS 15, FRANCE
来源
PHARMACOGENETICS | 1997年 / 7卷 / 05期
关键词
procainamide; CYP2D6; cytochrome P450; N-hydroxylation;
D O I
10.1097/00008571-199710000-00007
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Sequential oxidations at the arylamine moiety of the procainamide molecule leading to the formation of N-hydroxyprocainamide and its nitroso derivative may be responsible far lupus erythematosus observed in patients treated with the drug, The objective of the present study was to characterize major cytochrome P450 isozyme(s) involved in the N-hydroxylation of procainamide. Firstly, incubations were performed with microsomes from either lymphoblastoid cells or yeast transfected with cDNA encoding for specific human cytochrome P450 isozymes, Experiments performed with these enzyme expression systems indicated that the highest formation rate of N-hydroxyprocainamide was observed in the presence of CYP2D6 enriched microsomes, Additional experiments demonstrated that the formation rate of N-hydroxyprocainamide by CYP2D6 enriched microsomes was decreased from 45+/-4% to 93+/-1% by quinidine at: concentrations ranging from 30 nM to 100 mu M (all p < 0.05 vs control) and by approximately 75% by antibodies directed against CYP2D6. Secondly, incubations were performed with microsomes prepared from 15 human liver samples, Using this approach, an excellent correlation was observed between the formation rate of N-hydroxyprocainamide and dextromethorphan O-demethylase activity (CYP2D6: r = 0.9305; p < 0.0001). In contrast, no correlation could be established between N-hydroxyprocainamide formation rate and caffeine N3-demethylase (CYP1A2), coumarin 7-hydroxylase (CYP2A6), S-mephenytoin N-demethylase (CYP2B6), tolbutamide methylhydroxylase (CYP2C9), S-mephenytoin 4'-hydroxylase (CYP2C19), chlorzoxazone 6-hydroxylase (CYP2E1), dextromethorphan N-demethylase (CYP3A4), testosterone 6 beta-hydroxylase (CYP3A4/5) or lauric acid 12-hydroxylase (CYP4A11) activities. Furthermore, formation rate of N-hydroxyprocainamide was decreased in a concentration-dependent manner by quinidine (300 nM to 100 mu M) and by antibodies directed against CYP2D6 but not by furafylline 20 mu M (CYP1A2), ketoconazole 1 mu M (CYP3A4), sulfaphenazole 10 mu M (CYP2C9) or antibodies directed against CYP1A1/1A2, CYP2C, CYP2A6, CYP2E1 or CYP3A4/3A5. In conclusion the results obtained in the present study demonstrate that CYP2D6 is the major human cytochrome P450 isozyme involved in the formation of the reactive metabolite of procainamide, namely N-hydroxyprocainamide.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 49 条
[1]   DRUG-INDUCED ANTINUCLEAR ANTIBODIES AND LUPUS SYNDROMES [J].
ALARCONSEGOVIA, D .
DRUGS, 1976, 12 (01) :69-77
[2]   COLORIMETRIC DETERMINATION OF N-HYDROXYLATED METABOLITES IN MICROSOMAL STUDIES [J].
BELANGER, PM ;
GRECHBELANGER, O ;
BLOUIN, M .
ANALYTICAL BIOCHEMISTRY, 1981, 118 (01) :47-52
[3]  
Bigger J T Jr, 1969, Prog Cardiovasc Dis, V11, P515, DOI 10.1016/0033-0620(69)90004-8
[4]   ANTINUCLEAR ANTIBODY INDUCED BY PROCAINAMIDE - A PROSPECTIVE STUDY [J].
BLOMGREN, SE ;
CONDEMI, JJ ;
BIGNALL, MC ;
VAUGHAN, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1969, 281 (02) :64-&
[5]  
BUDINSKY RA, 1987, DRUG METAB DISPOS, V15, P37
[6]   POTENT INHIBITION OF YEAST-EXPRESSED CYP2D6 BY DIHYDROQUINIDINE, QUINIDINE, AND ITS METABOLITES [J].
CHING, MS ;
BLAKE, CL ;
GHABRIAL, H ;
ELLIS, SW ;
LENNARD, MS ;
TUCKER, GT ;
SMALLWOOD, RA .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (06) :833-837
[7]   PROCAINAMIDE DISPOSITION IN OBESITY [J].
CHRISTOFF, PB ;
CONTI, DR ;
NAYLOR, C ;
JUSKO, WJ .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1983, 17 (7-8) :516-522
[8]   CONCENTRATION-DEPENDENT CLEARANCE OF PROCAINAMIDE IN NORMAL SUBJECTS [J].
COYLE, JD ;
BOUDOULAS, H ;
MACKICHAN, JJ ;
LIMA, JJ .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1985, 6 (02) :159-165
[9]   A refilled substrate model for human cytochrome P450 2D6 [J].
deGroot, MJ ;
Bijloo, GJ ;
Martens, BJ ;
vanAcker, FAA ;
Vermeulen, NPE .
CHEMICAL RESEARCH IN TOXICOLOGY, 1997, 10 (01) :41-48
[10]   A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, p450 102, and P450 108 [J].
deGroot, MJ ;
Vermeulen, NPE ;
Kramer, JD ;
vanAcker, FAA ;
denKelder, GMDO .
CHEMICAL RESEARCH IN TOXICOLOGY, 1996, 9 (07) :1079-1091